ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Roma, Lazio

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Roma, Lazio, ITA:

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR)

with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Nab-Paclitaxel
Drug: Atezolizumab

Phase 3

Roche
Roche

Roma, Lazio, Italy and 75 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 228 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Rome, Italy and 516 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Rome, Italy and 505 other locations

to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received n...

Enrolling
Triple-Negative Breast Cancer
Biological: sac-TMT
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Roma, Lazio, Italy and 104 other locations

with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who car...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: nab-paclitaxel
Drug: placebo

Phase 3

Novartis
Novartis

Roma, RM, Italy and 76 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 360 other locations

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 286 other locations

monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

Phase 2

AstraZeneca
AstraZeneca

Roma, Italy and 140 other locations

with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in particip....

Enrolling
Ovarian Neoplasms
Triple Negative Breast Neoplasms
Drug: BMS-986340
Drug: BMS-936558-01

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Roma, Italy and 46 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems